KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Limited • KalVista Securities Holding Corporation • KalVista Pharmaceuticals (Ireland) Limited • KalVista Pharmaceuticals CH GmbH • KalVista Pharmaceuticals Japan K.K. ...

KALV stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$20.50

Low target

$19.00

High target

$22.00

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

16 Jan 25

8-K

KalVista Appoints Jeb Ledell as Chief Operating Officer

16 Dec 24

8-K

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

5 Dec 24

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

26 Nov 24

8-K

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

4 Nov 24

424B5

Prospectus supplement for primary offering

4 Nov 24

8-K

Entry into a Material Definitive Agreement

4 Nov 24

8-K

Submission of Matters to a Vote of Security Holders

4 Oct 24

8-K

KalVista Appoints Brian Piekos as Chief Financial Officer

10 Sep 24

Latest ownership filings

View all

Venrock Healthcare Capital Partners III, L.P.

3 Feb 25

Financial summary

Financial statements Chart KALV financial data

Quarter (USD)	Oct 24	Jul 24	Apr 24	Jan 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Apr 24	Apr 23	Apr 22	Apr 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	41.58 mm	41.58 mm	41.58 mm	41.58 mm	41.58 mm	41.58 mm
Cash burn (monthly)	(no burn)	1.34 mm	15.27 mm	14.30 mm	13.21 mm	10.21 mm
Cash used (since last report)	n/a	5.47 mm	62.28 mm	58.34 mm	53.90 mm	41.65 mm
Cash remaining	n/a	36.11 mm	-20.70 mm	-16.75 mm	-12.31 mm	-68.12 k
Runway (months of cash)	n/a	26.9	-1.4	-1.2	-0.9	-0.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

KALV institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	124	135	-8.1%
Opened positions	38	52	-26.9%
Closed positions	49	17	+188.2%
Increased positions	44	33	+33.3%
Reduced positions	25	32	-21.9%

13F shares	Current	Prev Q	Change
Total value	93.59 bn	948.45 bn	-90.1%
Total shares	140.92 mm	138.43 mm	+1.8%
Total puts	799.80 k	1.91 mm	-58.1%
Total calls	1.10 mm	1.68 mm	-34.4%
Total put/call ratio	0.7	1.1	-36.2%

Largest owners	Shares	Value	Change
ARE Alexandria Real Estate Equities	12.56 mm	$113.41 mm	0.0%
Venrock Healthcare Capital Partners III	11.81 mm	$103.53 mm	+1.3%
Vestal Point Capital	11.50 mm	$9.85 bn	+904.4%
VR Adviser	9.99 mm	$8.55 bn	+1.7%
Propel Bio Management	9.62 mm	$8.23 bn	+46.4%
BlackRock	9.30 mm	$7.96 bn	+33.9%
MS Morgan Stanley	8.82 mm	$7.55 bn	-11.0%
Schonfeld Strategic Advisors	8.76 mm	$7.50 bn	+2458.3%
Knoll Capital Management	5.80 mm	$4.96 bn	+4.0%
Vanguard	5.55 mm	$4.75 bn	+5.8%

Largest transactions	Shares	Bought/sold	Change
JHG Janus Henderson	35.79 k	-10.51 mm	-99.7%
Vestal Point Capital	11.50 mm	+10.36 mm	+904.4%
Schonfeld Strategic Advisors	8.76 mm	+8.42 mm	+2458.3%
Perceptive Advisors	860.00 k	-7.15 mm	-89.3%
T. Rowe Price Investment Management	5.42 mm	+5.21 mm	+2511.9%
BEN Franklin Resources	2.00 mm	-4.80 mm	-70.5%
Propel Bio Management	9.62 mm	+3.05 mm	+46.4%
BlackRock	9.30 mm	+2.35 mm	+33.9%
Adage Capital Partners GP, L.L.C.	1.96 mm	-2.15 mm	-52.3%
Qube Research & Technologies	1.95 mm	+1.94 mm	+15680.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KALV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Feb 25	Paul K. Audhya	Common Stock	Sell	Dispose S	No	No	10.02	2,394	23.99 k	102,940
24 Feb 25	Christopher Yea	Common Stock	Sell	Dispose S	No	No	10.02	1,918	19.22 k	93,952
22 Feb 25	Paul K. Audhya	Common Stock	Option exercise	Acquire M	No	No	0	5,000	0.00	105,334
22 Feb 25	Paul K. Audhya	RSU Common Stock	Option exercise	Dispose M	No	No	0	5,000	0.00	65,000
22 Feb 25	Christopher Yea	Common Stock	Option exercise	Acquire M	No	No	0	3,125	0.00	95,870
22 Feb 25	Christopher Yea	RSU Common Stock	Option exercise	Dispose M	No	No	0	3,125	0.00	40,625
21 Feb 25	Paul K. Audhya	RSU Common Stock	Grant	Acquire A	No	No	0	100,000	0.00	100,000
21 Feb 25	Brian Piekos	RSU Common Stock	Grant	Acquire A	No	No	0	80,000	0.00	80,000
21 Feb 25	Benjamin L Palleiko	RSU Common Stock	Grant	Acquire A	No	No	0	372,000	0.00	372,000
21 Feb 25	Christopher Yea	RSU Common Stock	Grant	Acquire A	No	No	0	60,000	0.00	60,000